FDA approves Novartis’ copycat of blockbuster Biogen drug
BioPharma Drive: Drug Pricing
AUGUST 25, 2023
According to one analyst, the approval was the last hurdle keeping Sandoz’s Tyruko from directly competing in the U.S. market against Biogen’s inflammation-regulating medicine Tysabri.
Let's personalize your content